Universal Beteiligungs und Servicegesellschaft mbH Lowers Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Universal Beteiligungs und Servicegesellschaft mbH reduced its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 58.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,094 shares of the biopharmaceutical company’s stock after selling 64,913 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in ACADIA Pharmaceuticals were worth $1,005,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. grew its stake in shares of ACADIA Pharmaceuticals by 113.0% in the third quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 756 shares in the last quarter. USA Financial Formulas purchased a new position in ACADIA Pharmaceuticals in the third quarter valued at $41,000. GAMMA Investing LLC grew its stake in ACADIA Pharmaceuticals by 25.8% during the 3rd quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 690 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in ACADIA Pharmaceuticals by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,465 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 884 shares during the period. Finally, Advyzon Investment Management LLC acquired a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at about $206,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Mark C. Schneyer sold 10,262 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total value of $243,106.78. Following the transaction, the executive vice president owned 53,338 shares in the company, valued at $1,263,577.22. The trade was a 16.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James M. Daly sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $22.37, for a total value of $671,100.00. Following the sale, the director directly owned 4,041 shares of the company’s stock, valued at approximately $90,397.17. This represents a 88.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 44,346 shares of company stock valued at $1,010,957. Insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock opened at $25.13 on Friday. The company has a market capitalization of $4.25 billion, a P/E ratio of 16.21, a PEG ratio of 6.22 and a beta of 0.68. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $28.35. The stock has a 50-day simple moving average of $26.49 and a 200-day simple moving average of $24.40.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.14 by $0.28. The company had revenue of $278.63 million for the quarter, compared to analyst estimates of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.The firm’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 earnings per share. As a group, analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ACAD. Piper Sandler set a $37.00 price objective on ACADIA Pharmaceuticals in a research report on Tuesday, December 16th. Royal Bank Of Canada dropped their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating on the stock in a research report on Thursday, November 6th. Needham & Company LLC restated a “buy” rating and issued a $34.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, January 5th. Mizuho boosted their target price on shares of ACADIA Pharmaceuticals from $24.00 to $29.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Finally, UBS Group increased their target price on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.16.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.